Tvardi Therapeutics (TVRD) CFO receives 17,500 stock options

Rhea-AI Filing Summary

Tvardi Therapeutics, Inc. reported an insider equity award to its Chief Financial Officer on a Form 4. The CFO received an employee stock option giving the right to buy 17,500 shares of common stock at an exercise price of $4.2 per share, granted on 12/16/2025 and expiring on 12/16/2035.

According to the vesting terms, 25% of the option shares vest on December 16, 2026. The remaining shares vest in equal monthly installments over the following 36 months, as long as the executive remains in continuous service through each vesting date. The transaction is reported as directly owned by the CFO and reflects standard stock-based compensation rather than an open-market stock purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Conn Avi Daniel

(Last) (First) (Middle)

C/O TVARDI THERAPEUTICS, INC.

3 SUGAR CREEK CTR BLVD, STE 525

(Street)

SUGAR LAND TX 77478

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tvardi Therapeutics, Inc. [ TVRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$4.2	12/16/2025		A		17,500		(1)	12/16/2035	Common Stock	17,500	$0	17,500	D

Explanation of Responses:

1. 25% of the shares subject to the option shall vest on December 16, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date.

	/s/ Dan Conn	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tvardi Therapeutics (TVRD) report in this Form 4?

The report shows that the Chief Financial Officer of Tvardi Therapeutics, Inc. received an employee stock option to purchase 17,500 shares of common stock at an exercise price of $4.2 per share.

Who is the insider involved in the latest Tvardi Therapeutics (TVRD) Form 4 filing?

The insider is an officer of Tvardi Therapeutics, Inc., serving as Chief Financial Officer. The filing is made by one reporting person and the ownership of the derivative securities is reported as direct.

What are the key terms of the Tvardi Therapeutics (TVRD) CFO stock option grant?

The CFO was granted an employee stock option on 12/16/2025 for 17,500 derivative securities linked to common stock, with an exercise price of $4.2 per share and an expiration date of 12/16/2035.

How does the Tvardi Therapeutics (TVRD) CFO option vest over time?

25% of the option shares vest on December 16, 2026. The remaining shares vest in equal monthly installments over the next 36 months, subject to the CFO’s continuous service through each vesting date.

Is the Tvardi Therapeutics (TVRD) CFO transaction a market purchase or sale of stock?

No, the Form 4 reports the grant of an employee stock option rather than an open-market stock purchase or sale. The option provides the right to buy common shares in the future at the fixed exercise price.

What type of security underlies the Tvardi Therapeutics (TVRD) CFO stock option?

The derivative security is an employee stock option (right to buy), and it is exercisable for 17,500 shares of common stock of Tvardi Therapeutics, Inc..